GPT and Cirrhosis: Recently, Agile 3+ and 4 scores were established, combining LSM with inherent demographic data (age, sex, and the presence of type 2 diabetes) and serum biomarkers (ALT, AST, and platelets) to better diagnose advanced fibrosis and cirrhosis in MASLD, with diagnostic efficacy AUC of 0.85, similar to that of LSM (AUC 0.83, p= 0.142) (54–57).